NR1H4 and metabolic dysfunction-associated steatohepatitis: The use of acid obeticholic—a potent activator of the farnesoid X-nuclear receptor that regulates bile acid, glucose, and cholesterol homeostasis—also resulted in the improvement of steatosis, hepatocellular ballooning, and lobular inflammation in the FLINT trial.150 Compared to placebo, the NASH resolution was obtained in 22% of treated patients.